Abgenix, SangStat end ABX-CBL development

ABGX and SANG said they will end development of ABX-CBL, an anti- CD147 antibody, after the compound failed to increase survival at 180 days compared to Atgam anti-thymocyte globulin in a Phase II/III trial in patients with acute steroid-refractory graft versus host disease (GvHD). The companies said the 180-day survival rate of ABX-CBL patients was similar to Atgam, which is marketed by Pharmacia (PHA). ...